A Clinical trial to establish the appropriate line of management of Non Muscle Invasive Bladder Cancers who have had their intravesical BCG therapy interrupted
Phase 4
Not yet recruiting
- Conditions
- Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhereHealth Condition 2: C679- Malignant neoplasm of bladder, unspecified
- Registration Number
- CTRI/2020/06/025798
- Lead Sponsor
- one
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.Patients aged more than 18 years
2.Patients having high risk NMIBC (T1 or CIS or HG, {multiple, recurrent, and large TaG1G2 all features must be present} ) and Intermediate risk (TaG1/G2 with multiple, recurrent, large tumour) (according to EAU risk stratification) who were planned for BCG therapy but not started.
3.Patients who have received intravesical BCG therapy and whose treatment was not complete as on 25th March, 2020
Exclusion Criteria
1.Low risk group (Ta LG, < 3cm, solitary, no CIS) (according to EAU risk stratification)
2.History of BCG intolerance
3.Patients who have completed BCG intravesical therapy as on march 25th, 2020.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method